Active Ingredient History
Erenumab, sold under the brand name Aimovig, is a medication which blocks the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. It is administered by subcutaneous injection. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Migraine Disorders (approved 2018)
Angina, Stable (Phase 2)
Brain Concussion (Phase 2)
Brain Diseases (Phase 2)
Chronic Pain (Phase 2)
Cluster Headache (Phase 2)
Facial Pain (Phase 4)
Headache (Phase 4)
Headache Disorders, Primary (Phase 2)
Healthy Volunteers (Phase 1)
Migraine Disorders (Phase 4)
Neurilemmoma (Phase 2)
Post-Concussion Syndrome (Phase 2)
Post-Traumatic Headache (Phase 2)
Rosacea (Phase 2)
Schwann Cells (Phase 2)
Sinusitis (Phase 4)
Temporomandibular Joint Disorders (Phase 2)
Trigeminal Autonomic Cephalalgias (Phase 2)
Trigeminal Nerve Diseases (Phase 2)
Trigeminal Neuralgia (Phase 2)
Vasomotor System (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
